Tirzepatide 60mg (10 Vials / Kit)

Tirzepatide 60mg is the largest kit in the range – ten lyophilised vials of the dual GIP/GLP-1 receptor agonist, giving the lowest cost per milligram for institutional and long-duration research. Every batch is independently tested by Janoshik for identity and purity (≥99% by HPLC) and shipped with a batch-specific certificate of analysis.

What is Tirzepatide?

Tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide engineered by Eli Lilly to activate two incretin receptors at once: the glucose-dependent insulinotropic polypeptide receptor (GIPR) and the glucagon-like peptide-1 receptor (GLP-1R). Built on the native GIP sequence with a C20 fatty di-acid side chain that binds albumin, it has a half-life of about five days, which is why once-weekly dosing was used throughout its clinical development. It was the first “dual agonist” (or “twincretin”) to reach the market and is the direct predecessor of the triple agonist retatrutide.

What the research shows

• Type 2 diabetes – SURPASS programme. Across five phase 3 trials, tirzepatide lowered HbA1c by up to 2.6 percentage points and outperformed semaglutide 1mg head-to-head (SURPASS-2, NEJM 2021). It was approved by the FDA as Mounjaro in May 2022.
• Obesity – SURMOUNT-1 (NEJM, 2022). In 2,539 adults without diabetes, 72 weeks of tirzepatide produced mean weight reductions of 15%, 19.5% and 20.9% at 5, 10 and 15mg – with more than half of participants on the top dose losing at least 20% of body weight. Approved as Zepbound in November 2023.
• Head-to-head with semaglutide – SURMOUNT-5 (2025). Tirzepatide 15mg produced 20.2% weight loss versus 13.7% for semaglutide 2.4mg over 72 weeks.
• Obstructive sleep apnoea. The SURMOUNT-OSA trials showed large reductions in apnoea–hypopnoea index, leading to FDA approval for moderate-to-severe OSA with obesity in December 2024.
• Cardiometabolic markers. Trials consistently report reductions in liver fat, triglycerides, blood pressure and inflammatory markers; the SURPASS-CVOT cardiovascular-outcomes trial reported non-inferiority to dulaglutide in 2025.

Mechanism under investigation

GLP-1R activation slows gastric emptying, increases glucose-dependent insulin secretion and reduces appetite through central pathways. Adding GIPR activation appears to enhance insulin sensitivity in adipose tissue, improve lipid handling and reduce the nausea that limits GLP-1 monotherapy – the combination is why tirzepatide exceeds the efficacy of single-receptor agonists in preclinical and clinical studies.

Research applications

Tirzepatide is used in laboratory models of obesity and energy balance, glucose homeostasis and beta-cell function, hepatic steatosis (MASLD/MASH), incretin-receptor pharmacology, and as the reference dual agonist in comparison studies against semaglutide and retatrutide.

Specifications

• Contents: 10 vials × 60mg Tirzepatide
• Form: Lyophilised powder
• Molecular Formula: C225H348N48O68
• Molecular Weight: ~4813.5 g/mol
• Purity: ≥99% (HPLC), Janoshik tested
• Storage: Store lyophilised at -20°C; reconstituted solution at 2–8°C, protected from light

For laboratory research use only. Not for human or veterinary use. Research-grade tirzepatide is not a substitute for, or equivalent to, any approved pharmaceutical product.